top of page

MWOF Executive Team

The Michael W. Oglesby Foundation is a 501 c3 nonprofit organization established March 18, 2016.

Our Foundation is established in memory of Michael “Faj” Oglesby. We serve to educate the community about pancreatic cancer, to provide and enhance support for those affected, and to increase survival rates by fundraising for early detection through research. Our mission is to bring hope and treatment to everyone touched by pancreatic cancer. Our vision is a world where pancreatic cancer is the most curable cancer.

The Michael W. Oglesby Foundation is a member of the World Pancreatic Cancer Coalition.


MWOF Tax Identification Number: 81-2053135

Diane M. Oglesby

President / Co-Founder

Fundraising Committee

Shannon M. Huber

Vice President / Co-Founder

Fundraising Committee

Mary Ellen Oglesby


Brittany A. Keating

Treasurer / Co-Founder

Fundraising Director

Thomas J. Oglesby

Chairman of the Board / Co-Founder

Audra M. McMahon

Social Media Manager


Pancreatic Cancer Facts

  • Pancreatic cancer is the 3rd leading cause of cancer related death in the US.

  • It is expected to surpass colorectal cancer to become the 2nd leading cause of cancer related death in 2020.

  • Over 90% of pancreatic cancer patients will die within 5 years of diagnosis, over 70% in the first year.

  • Symptoms of pancreatic cancer are vague - pain (in the abdomen or back), weight loss, jaundice, nausea, loss of appetite, and change in stool.

  • Diagnosis often happens in late stages of the disease due to lack of reliable early detection methods. 

  • Pancreatic cancer survival rates have not improved significantly over 40+ years.

Where Your Donations Go

  • Directly to local individuals for support in battling pancreatic cancer.

  • Campaigns to generate awareness of pancreatic cancer.

  • To Midwest-based healthcare and research dedicated to pancreatic cancer, including:

    • Radiographic outcomes research - using imagining in new ways to detect pancreatic cancer earlier. 

    • Imaging ex-vivo - imaging the tumor after it has been excised to gain prevention and treatment insight.

    • Imaging in premalignant patients – evaluating premalignant pancreatic cystic lesions (MRI texture analysis.)

    • Evaluation of cancer care coordination - creating a better system for patients to navigate from diagnosis to multidisciplinary care.

Partners in the Fight Against Pancreatic Cancer

Dr. Sean Ronnekleiv-Kelly

Assistant Professor

Division of Surgical Oncology

University of Wisconsin-Madison

Dr. Sean Ronnekleiv-Kelly is an Assistant Professor in the Department of Surgery at the University of Wisconsin School of Medicine and Public Health (UW SMPH), Division of Surgical Oncology. His clinical focus is pancreas cancer and hepatobiliary cancers, and his research centers on evaluating how an 'environmental sensor' class of proteins affects pancreas cancer development and spread. He completed a surgical residency at UW SMPH and during that time recognized the complexity of cancer and the need for research to achieve breakthroughs for patients with cancer. He then completed a Complex General Surgical Oncology Fellowship at Johns Hopkins, where his extensive exposure to patients with pancreas and hepatobiliary cancer caused him to appreciate the limited therapeutic options available for these patients. In particular, he recognized that pancreas cancer was a malignancy where immense advancements in treatment are needed. Therefore, his laboratory focuses on manipulating the Per-Arnt-Sim family of 'environmental sensor' proteins, such as those involved in circadian rhythm, to improve preventive and therapeutic strategies for patients with pancreas cancer. 

bottom of page